291 related articles for article (PubMed ID: 26028416)
1. [Bias and confounding: pharmacoepidemiological study using administrative database].
Nojiri S
Yakugaku Zasshi; 2015; 135(6):793-808. PubMed ID: 26028416
[TBL] [Abstract][Full Text] [Related]
2. Administrative database research has unique characteristics that can risk biased results.
van Walraven C; Austin P
J Clin Epidemiol; 2012 Feb; 65(2):126-31. PubMed ID: 22075111
[TBL] [Abstract][Full Text] [Related]
3. [Application of disease-risk score in pharmacoepidemiologic studies].
Zhao HY; Zhan SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):261-266. PubMed ID: 28231678
[TBL] [Abstract][Full Text] [Related]
4. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.
Prada-Ramallal G; Takkouche B; Figueiras A
BMC Med Res Methodol; 2019 Mar; 19(1):53. PubMed ID: 30871502
[TBL] [Abstract][Full Text] [Related]
5. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
Conte C; Vaysse C; Bosco P; Noize P; Fourrier-Reglat A; Despas F; Lapeyre-Mestre M
Therapie; 2019 Apr; 74(2):279-288. PubMed ID: 30824175
[TBL] [Abstract][Full Text] [Related]
6. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores.
Eng PM; Seeger JD; Loughlin J; Clifford CR; Mentor S; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):297-305. PubMed ID: 18215000
[TBL] [Abstract][Full Text] [Related]
7. Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors?
Jackson ML; Nelson JC; Jackson LA
Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):858-65. PubMed ID: 21671442
[TBL] [Abstract][Full Text] [Related]
8. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies.
Takeuchi Y; Shinozaki T; Matsuyama Y
BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575
[TBL] [Abstract][Full Text] [Related]
9. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
10. Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.
Kim DH; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):891-901. PubMed ID: 24962929
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
Etminan M; Gill S; Fitzgerald M; Samii A
J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
[TBL] [Abstract][Full Text] [Related]
12. Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research.
Girman CJ; Faries D; Ryan P; Rotelli M; Belger M; Binkowitz B; O'Neill R;
J Comp Eff Res; 2014 May; 3(3):259-70. PubMed ID: 24969153
[TBL] [Abstract][Full Text] [Related]
13. The missing cause approach to unmeasured confounding in pharmacoepidemiology.
Abrahamowicz M; Bjerre LM; Beauchamp ME; LeLorier J; Burne R
Stat Med; 2016 Mar; 35(7):1001-16. PubMed ID: 26932124
[TBL] [Abstract][Full Text] [Related]
14. Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force.
Kumamaru H; Togo K; Kimura T; Koide D; Iihara N; Tokumasu H; Imai S
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5680. PubMed ID: 37650434
[TBL] [Abstract][Full Text] [Related]
15. Methods to adjust for bias and confounding in critical care health services research involving observational data.
Wunsch H; Linde-Zwirble WT; Angus DC
J Crit Care; 2006 Mar; 21(1):1-7. PubMed ID: 16616616
[TBL] [Abstract][Full Text] [Related]
16. Core concepts in pharmacoepidemiology: Measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology.
Thai TN; Winterstein AG
Pharmacoepidemiol Drug Saf; 2024 Mar; 33(3):e5683. PubMed ID: 37752827
[TBL] [Abstract][Full Text] [Related]
17. [Secondary Data for Pharmacoepidemiological Research - Making the Best of It!].
Pigeot I; Kollhorst B; Didelez V
Gesundheitswesen; 2021 Nov; 83(S 02):S69-S76. PubMed ID: 34695869
[TBL] [Abstract][Full Text] [Related]
18. Martingale residual-based method to control for confounders measured only in a validation sample in time-to-event analysis.
Burne RM; Abrahamowicz M
Stat Med; 2016 Nov; 35(25):4588-4606. PubMed ID: 27306611
[TBL] [Abstract][Full Text] [Related]
19. Addressing unmeasured confounding in comparative observational research.
Zhang X; Faries DE; Li H; Stamey JD; Imbens GW
Pharmacoepidemiol Drug Saf; 2018 Apr; 27(4):373-382. PubMed ID: 29383840
[TBL] [Abstract][Full Text] [Related]
20. Bias: considerations for research practice.
Gerhard T
Am J Health Syst Pharm; 2008 Nov; 65(22):2159-68. PubMed ID: 18997149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
